

To valued customers/ suppliers/ business partners,

We, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. ("Mindray"), are pleased to announce that we have completed the acquisition of 100% shares of HyTest Invest Oy and its subsidiaries ("HyTest"). With the closing of the transaction, HyTest becomes Mindray's wholly-owned subsidiary.

Mindray is a leading high-tech medical device manufacturer, and one of the global leaders in medical innovation. The company's business covers patient monitor & life support, *In-vitro* diagnostics and medical imaging system. Mindray is committed to create customer value with comprehensive solutions through cutting-edge technological innovation, improving medical conditions and efficiency. In October 2018, Mindray was listed in Shenzhen Stock Exchange (Ticker: 300760).

For more information on Mindray, visit www.mindray.com

HyTest, founded in 1994 and headquartered in Finland, is a global leading provider of antibodies and antigens focused on the IVD market. HyTest has extensive expertise in antibody and antigen design, innovation and production. The company has gained market leading positions in several key segments, including cardiac markers, inflammation, tumor markers and infectious diseases etc. In 2004, HyTest's cardiac troponin complex material was chosen by AACC as a raw material for the international troponin standard.

For more information on HyTest, visit HyTest global: www.hytest.fi

Upon the completion of the acquisition, HyTest will retain its independent operations and position as a leading antibodies & antigens supplier. HyTest will also continue to provide stable and high-quality products to global IVD customers, with competitive prices. HyTest will maintain its existing sales and service policies, and continue to honor existing contracts.

Mindray will strive to ensure HyTest's team stability and motivation. HyTest will have Mindray's firm support to continuously increase R&D investment, strengthen technological innovation and academic exploration, enhance its core competitiveness, and maintain its world leading position in the IVD focused antibody & antigen market.

We believe that the acquisition will bring many synergies to both parties. We expect HyTest to provide better products and services to our customers, broaden development opportunities for our employees, and enable HyTest to stay ahead in the market.

Thank you for staying with HyTest, and hope that you will continue to support us in the future.

Best Regards,

Shenzhen Mindray Bio-Medical Electronics Co., Ltd.



September 23, 2021